Ascendiant Capital Markets Lowers Vivos Therapeutics (NASDAQ:VVOS) Price Target to $5.50

Vivos Therapeutics (NASDAQ:VVOS) had its target price decreased by equities research analysts at Ascendiant Capital Markets from $6.50 to $5.50 in a report released on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Ascendiant Capital Markets’ price target suggests a potential upside of 155.81% from the stock’s current price.

A number of other equities research analysts also recently weighed in on VVOS. Zacks Research upgraded shares of Vivos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday. Weiss Ratings reissued a “sell (e+)” rating on shares of Vivos Therapeutics in a research note on Wednesday, October 8th. HC Wainwright initiated coverage on shares of Vivos Therapeutics in a research report on Monday, November 17th. They issued a “buy” rating and a $7.00 target price on the stock. Finally, Wall Street Zen downgraded shares of Vivos Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 10th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $4.92.

Vivos Therapeutics Trading Up 3.9%

Shares of VVOS stock opened at $2.15 on Wednesday. Vivos Therapeutics has a fifty-two week low of $1.98 and a fifty-two week high of $7.95. The stock’s fifty day moving average price is $2.66 and its two-hundred day moving average price is $3.46. The company has a debt-to-equity ratio of 3.31, a quick ratio of 0.78 and a current ratio of 0.78. The company has a market cap of $19.33 million, a PE ratio of -1.21 and a beta of 6.88.

Vivos Therapeutics (NASDAQ:VVOS) last announced its quarterly earnings data on Wednesday, November 19th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.04. Vivos Therapeutics had a negative return on equity of 351.28% and a negative net margin of 98.77%.The business had revenue of $6.78 million during the quarter, compared to the consensus estimate of $4.49 million. Equities analysts predict that Vivos Therapeutics will post -1.79 EPS for the current fiscal year.

Institutional Trading of Vivos Therapeutics

Several institutional investors have recently modified their holdings of the business. XTX Topco Ltd bought a new position in Vivos Therapeutics during the 2nd quarter worth $65,000. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Vivos Therapeutics in the second quarter valued at about $220,000. Finally, Connective Capital Management LLC acquired a new stake in shares of Vivos Therapeutics in the third quarter valued at about $620,000. Institutional investors own 26.35% of the company’s stock.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.